Temporal trends in genital warts among individuals covered by the public prescription drug insurance plan in the province of Quebec, Canada, from 1998 to 2007

Journal of Lower Genital Tract Disease

Volumn 17, Issue 2, 2013, Pages 147-153

  Steben, Marc ^a   Ouhoummane, Najwa ^a   Rodier, Caroline ^b   Brassard, Paul ^c,d  

^a INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^b Merck Canada Inc   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Condyloma; Epidemiology; Genital warts; Human papillomavirus

Indexed keywords

FLUOROURACIL; IMIQUIMOD; PODOPHYLLOTOXIN;

ADULT; ARTICLE; CANADA; CONDYLOMA ACUMINATUM; DATA BASE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PROCEDURES; TREATMENT DURATION; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIVIRAL AGENTS; CONDYLOMATA ACUMINATA; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; FLUOROURACIL; HUMANS; INCIDENCE; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PODOPHYLLOTOXIN; PREVALENCE; QUEBEC; YOUNG ADULT;

EID: 84876155957     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e31825c3915     Document Type: Article

References (31)

1. Kliewer EV, Demers AA, Elliott L, Lotocki R, Butler JR, Brisson M. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex TransmDis 2009; 36: 380-6.
2. Drolet M, Brisson M, Maunsell E, Franco EL, Coutlee F, Ferenczy A, et al. The impact of anogenital warts on healthrelated quality of life: a 6-month prospective study. Sex Transm Dis 2011;38: 949-56.
3. Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K. Genital warts and cost of care in England. Sex Transm Infect 2011;87: 464-8.
4. Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E. Incidence of anogenital warts in Germany: a populationbased cohort study. BMC Infect Dis 2010;10: 360.
5. Hoy T, Singhal PK, Willey VJ, Insinga RP. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009;25: 2343-51.
6. Chuang TY, Perry HO, Kurland LT, Ilstrup DM. Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features. Arch Dermatol 1984;120: 469-75.
7. Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009;85: 111-5.
8. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital wartsYrelated healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004;31: 748-52.
9. Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S. Genital warts incidence and healthcare resource utilisation in Australia. Sex Transm Infect 2010;86: 181-6.
10. Jin F, Prestage GP, Kippax SC, Pell CM, Donovan B, Templeton DJ, et al. Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sex Transm Dis 2007;34: 488-93.
11. Aubin F, Pretet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, et al. Human papillomavirus genotype distribution in external Acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008;47: 610-5.
12. Garland SM, Steben M, SingsHL, JamesM, Lu S,Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199: 805-14.
13. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009;85: 499-502.
14. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011;11: 39-44.
15. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011;87: 544-7.
16. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48: 999-1009.
17. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 2002;186: 462-9.
18. Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008;198: 827-35.
19. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16: 709-15.
20. National Cancer Institute. Joinpoint regression program. Version 3.5. Bethesda: U.S. National Institutes of Health 2011. Available at: http://surveillance.cancer.gov/joinpoint. Accessed November 2011.
21. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007;196: 1447-54.
22. Simms I, Fleming DM, Lowndes CM, Smith GE, Chapman RS. Surveillance of sexually transmitted diseases in general practice: a description of trends in the Royal College of General PractitionersWeekly Returns Service between 1994 and 2001. Int J STD AIDS 2006;17: 693-8.
23. Simms I, Fairley CK. Epidemiology of genital warts in England andWales: 1971 to 1994. Genitourin Med 1997;73: 365-7.
24. United Kingdom.Health protection agency. Continued increase in sexually transmitted infections: an analysis of data from UK genitourinary medicine clinics up to 2007. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb- C/1216022446179. Accessed November 2011.
25. Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis 2008;35: 357-60.
26. Van Den Eeden SK, Habel LA, Sherman KJ, McKnight B, Stergachis A, Daling Jr. Risk factors for incident and recurrent Condylomata acuminata among men. A population-based study. Sex Transm Dis 1998;25: 278-84.
27. Khan A, Hussain R, Schofield M. Correlates of sexually transmitted infections in young Australian women. Int J STD AIDS 2005;16: 482-7.
28. Silverberg MJ, Ahdieh L, Munoz A, Anastos K, Burk RD, Cu-Uvin S, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002;29: 427-35.
29. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36: 1397-403.
30. Arima Y, Winer RL, Feng Q, Hughes JP, Lee SK, Stern ME, et al. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis 2010;202: 1181-4.
31. Hillemanns P, Breugelmans JG, Gieseking F, Benard S, Lamure E, Littlewood KJ, et al. Estimation of the incidence of genital warts and the cost of illness in Germany: a crosssectional study. BMC Infect Dis 2008;8: 76.